King highlights the pressing need for better treatment options for advanced and recurrent prostate cancer ... where mechanical therapies like focused ultrasound are used alongside small-molecule ...

#cancerresearch’ The study sheds new light on how low-intensity focused ultrasound and soluble TRAIL specifically destroy cancer cells within the compact environment of a primary prostate cancer ...

Background: National guidelines recommend obtaining prostate gland volume (PGV) prior to benign prostate hyperplasia (BPH) surgery. Measurement of PGV with handheld ultrasound (HUS) probes shows ...

Myriad is planning to launch its first AI-driven prostate cancer clinical test later this year.

Feb. 21, 2025 — Researchers have investigated how microbubbles tiny gas bubbles can deliver drugs into cells in a targeted manner using ultrasound. For the first time, they have visualized how ...

Combining an existing small-molecule protein therapy called tumor necrosis factor related apoptosis-inducing ligand (TRAIL) with focused ultrasound (FUS) can significantly reduce tumor size and burden ...

WOLVERINE meta-analysis indicates MDT improves survival outcomes in oligometastatic prostate cancer, enhancing PFS, rPFS, and CRFS compared with SOC alone. The study included 472 patients, with a ...

Here’s a health tip that might sound pretty good to many guys: Have more sex, or masturbate more, and you might lower your odds of getting prostate cancer. Research suggests that the more often ...

Recently, licensed and emerging treatments for metastatic castrate-resistant prostate cancer are transforming ... to confer a terminal prognosis, with a median survival of 12 months from ...

So, what will the median income for the upper-middle class be in 2025? Here’s a look at the factors involved so you can see if you fit into this category. Quick Take: Median Upper-Middle-Class ...

In mCRPC patients, Talzenna + Xtandi cut death risk by 20%, extending median OS to 45.8 months vs ... with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous ...